FI962619A - Autoantigeenistä johdettuja uusia peptidejä autoimmuunitautien immunoterapiassa käyttöä varten - Google Patents

Autoantigeenistä johdettuja uusia peptidejä autoimmuunitautien immunoterapiassa käyttöä varten Download PDF

Info

Publication number
FI962619A
FI962619A FI962619A FI962619A FI962619A FI 962619 A FI962619 A FI 962619A FI 962619 A FI962619 A FI 962619A FI 962619 A FI962619 A FI 962619A FI 962619 A FI962619 A FI 962619A
Authority
FI
Finland
Prior art keywords
peptides
autoantigen
seq
pct
autoimmune diseases
Prior art date
Application number
FI962619A
Other languages
English (en)
Swedish (sv)
Other versions
FI118472B (fi
FI962619A0 (fi
Inventor
Anna Maria Helena Boots
Gijsbertus Francisc Verheijden
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of FI962619A publication Critical patent/FI962619A/fi
Publication of FI962619A0 publication Critical patent/FI962619A0/fi
Application granted granted Critical
Publication of FI118472B publication Critical patent/FI118472B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI962619A 1994-10-27 1996-06-25 Autoantigeenistä johdettuja uusia peptidejä autoimmuunitautien immunoterapiassa käyttöä varten FI118472B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP94203128 1994-10-27
EP94203128 1994-10-27
EP95200886 1995-04-07
EP95200886 1995-04-07
EP9504201 1995-10-25
PCT/EP1995/004201 WO1996013517A1 (en) 1994-10-27 1995-10-25 Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases

Publications (3)

Publication Number Publication Date
FI962619A true FI962619A (fi) 1996-06-25
FI962619A0 FI962619A0 (fi) 1996-06-25
FI118472B FI118472B (fi) 2007-11-30

Family

ID=26136688

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962619A FI118472B (fi) 1994-10-27 1996-06-25 Autoantigeenistä johdettuja uusia peptidejä autoimmuunitautien immunoterapiassa käyttöä varten

Country Status (24)

Country Link
US (1) US5736507A (fi)
EP (1) EP0733065B1 (fi)
JP (1) JP3755894B2 (fi)
KR (1) KR100485979B1 (fi)
CN (1) CN1161379C (fi)
AT (1) ATE177756T1 (fi)
AU (1) AU696827B2 (fi)
BR (1) BR9506377A (fi)
CA (1) CA2173874A1 (fi)
DE (1) DE69508380T2 (fi)
DK (1) DK0733065T3 (fi)
ES (1) ES2130672T3 (fi)
FI (1) FI118472B (fi)
GR (1) GR3030296T3 (fi)
HK (1) HK1002012A1 (fi)
HU (1) HU218027B (fi)
IL (1) IL115744A (fi)
MX (1) MX9602495A (fi)
NO (1) NO316703B1 (fi)
NZ (1) NZ295659A (fi)
PL (1) PL183761B1 (fi)
RU (1) RU2178797C2 (fi)
TR (1) TR199501326A2 (fi)
WO (1) WO1996013517A1 (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6881824B1 (en) 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
IL120561A0 (en) 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
RU2233290C2 (ru) 1998-07-23 2004-07-27 Акцо Нобель Н.В. Новые пептиды для применения в иммунотерапии аутоиммунных заболеваний
EP1100526A2 (en) * 1998-07-23 2001-05-23 Akzo Nobel N.V. USE OF HC gp-39 IN IMMUNE DISEASES
CA2386398A1 (en) * 1999-10-18 2001-04-26 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2003009808A2 (en) * 2001-07-24 2003-02-06 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
EP1928496A4 (en) * 2005-08-31 2011-01-05 Medimmune Inc C / CLP ANTAGONISTS AND METHOD OF USE
RU2302872C9 (ru) * 2006-06-22 2008-12-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее функции хрящевой ткани, и способ его получения
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
KR101699554B1 (ko) 2007-08-15 2017-01-25 서카시아 리미티드 백신용 펩티드
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
SI2153841T2 (sl) 2008-08-15 2016-02-29 Circassia Limited Cepivo, ki obsega peptide Amb a 1, za uporabo pri zdravljenju alergije na ambrozijo
JP5746053B2 (ja) 2009-02-05 2015-07-08 サーカッシア リミテッド ワクチン用ペプチド
ES2600932T3 (es) * 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323898A (ja) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices

Also Published As

Publication number Publication date
CN1168677A (zh) 1997-12-24
KR100485979B1 (ko) 2006-01-27
FI118472B (fi) 2007-11-30
EP0733065B1 (en) 1999-03-17
CN1161379C (zh) 2004-08-11
NO962695D0 (no) 1996-06-26
AU696827B2 (en) 1998-09-17
RU2178797C2 (ru) 2002-01-27
NO962695L (no) 1996-06-26
HU218027B (hu) 2000-05-28
DE69508380D1 (de) 1999-04-22
JPH09507861A (ja) 1997-08-12
DE69508380T2 (de) 1999-09-09
WO1996013517A1 (en) 1996-05-09
PL183761B1 (pl) 2002-07-31
HK1002012A1 (en) 1998-07-24
BR9506377A (pt) 1997-09-16
ATE177756T1 (de) 1999-04-15
US5736507A (en) 1998-04-07
NO316703B1 (no) 2004-04-13
HUT74847A (en) 1997-02-28
IL115744A0 (en) 1996-01-19
EP0733065A1 (en) 1996-09-25
AU3925295A (en) 1996-05-23
CA2173874A1 (en) 1996-05-09
MX9602495A (es) 1997-05-31
ES2130672T3 (es) 1999-07-01
TR199501326A2 (tr) 1996-06-21
IL115744A (en) 2000-07-16
DK0733065T3 (da) 1999-10-11
KR960705848A (ko) 1996-11-08
GR3030296T3 (en) 1999-09-30
NZ295659A (en) 1998-02-26
JP3755894B2 (ja) 2006-03-15
PL315198A1 (en) 1996-10-14
FI962619A0 (fi) 1996-06-25
HU9601401D0 (en) 1996-07-29

Similar Documents

Publication Publication Date Title
FI962619A (fi) Autoantigeenistä johdettuja uusia peptidejä autoimmuunitautien immunoterapiassa käyttöä varten
Ugrinovic et al. A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis.
Crowe et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features
NZ332311A (en) Use of autoantigen HC gp-39 and proteins structurally related thereto in immunotherapy of autoimmune diseases particularly rheumatoid arthritis
ATE252640T1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
FI960980A0 (fi) Menetelmiä antigeenispesifisen T-solutoleranssin indusoimiseksi
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
Monneaux et al. Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins
NZ332427A (en) Peptides suitable for use in antigen specific immunosuppressive therapy
ATE248602T1 (de) Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
ATE185151T1 (de) Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten
Choudhury et al. Immune responses to citrullinated and homocitrullinated peptides in healthy donors are not restricted to the HLA SE shared allele and can be selected into the memory pool
TR200100175T2 (tr) Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
Buus et al. The Interaction between MHC Class II Molecules and Immunogenic Peptides
Dai Parameters influencing generation of cryptic pathogenic T-cell epitopes in thyroglobulin
Bach GAD Peptide VaccinesforT1DM: Not Just a Blueprint?

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: N.V. ORGANON

Free format text: N.V. ORGANON

FG Patent granted

Ref document number: 118472

Country of ref document: FI